Clinical trials: Depressive Disorder NOS
Major Depressive Disorder
Empower: tDCS for Major Depressive Disorder at Home
A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home.
- Trial name
- NCT05202119
- Testing
- Transcranial direct current stimulation
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 174 people
- Sponsor
- Flow Neuroscience AB
Depressive Disorder, Major
A Study to Evaluate the Effect of Food on LY2216684
This study will evaluate the effect of food on LY2216684. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last…
- Trial name
- NCT01389765
- Testing
- LY2216684
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Pyxis (NCT01360645)
- Testing
- OPC-34712 + ADT
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 826 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
MAJOR DEPRESSIVE DISORDER
Influenza Challenge in Mood Disorders
The aim of this project is to evaluate the efficacy of the influenza vaccine in individuals with major depressive disorder (MDD) as well as to elucidate the nature of the immunological abnormalities in MDD using a…
- Trial name
- NCT02415166
- Testing
- INFLUENZA VACCINE
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Laureate Institute for Brain Research, Inc.
Major Depressive Disorder
Epigenetic Regulation of BDNF in Major Depression
The investigators will (1) detect the associations between brain-derived neurotrophic factor (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive…
- Trial name
- NCT01182103
- Where
- Taiwan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Bipolar Disorder, Major Depressive Disorder
Study Using Pregnenolone to Treat Bipolar Depression
Primary purpose of this study is to determine if pregnenolone supplementation is associated with greater improvement in depressive symptoms of patients with bipolar disorder.
- Trial name
- NCT01409096
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Texas Southwestern Medical Center
Depression, Major Depressive Disorder
eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
The objective of this randomized controlled trial is to evaluate whether the investigators modernized IMPACT intervention for depression (eIMPACT), delivered before the onset of cardiovascular disease (CVD), reduces the risk of…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT02458690
- Testing
- Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Indiana University
Depression
Role of Slow-wave Activity and Plasticity in MDD
The hypothesis underlying this proposal is that deficits of synaptic plasticity underlie the slow-wave activity (SWA) abnormalities observed n major depressive disorder (MDD), and that manipulating SWA may serve to circumvent…
- Trial name
- SWIP (NCT04150718)
- Testing
- slow-wave disruption
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study
This protocol, "Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder (MDD): A Functional Connectivity Magnetic Resonance Imaging (fcMRI) Study," is an open-label pilot treatment…
- Trial name
- NCT01162382
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder.
- Trial name
- NCT00863798
- Testing
- Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg
- Where
- 24 sites in United States
- Volunteers
- 682 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postpartum Depression
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).
- Trial name
- NCT02285504
- Testing
- SAGE-547
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.
- Trial name
- NCT00596817
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 639 people
- Sponsor
- H. Lundbeck A/S
Major Depression, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
- Conditions
- Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
- Trial name
- NCT00296725
- Testing
- Fluoxetine, Imipramine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder
Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function
The purpose of this study is to understand the effectiveness of a ten-week internet-based cognitive behavioral therapy (iCBT) treatment on improving depressive symptoms, coping and resilience skills, and cognitive processing.
- Trial name
- iCBT (NCT01598922)
- Testing
- Internet Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression
This study was conducted to understand the use of a mobile app (titled Pathway) to help patients track depression symptoms, medications, side effects, and goals in addition to the usual care with their doctor.
- Trial name
- NCT04891224
- Testing
- Pathway Platform mobile app
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Wake Forest University Health Sciences
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Imaging Dopamine Release in Depression
This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict…
- Trial name
- NCT02033369
- Testing
- Pramipexole
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Borderline Personality Disorder
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young…
- Trial name
- NCT01103180
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Major Depressive Disorder
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.
- Trial name
- NCT02389816
- Testing
- Vortioxetine
- Where
- 47 sites in Japan
- Volunteers
- 493 people
- Sponsor
- Takeda